SOUTH SAN FRANCISCO, Calif. – September 5, 2001 – AGY Therapeutics, a privately-held biotechnology company, announced today that Roman Urfer, Ph.D., has been appointed Vice President of Drug Discovery and Development. Dr. Urfer joins AGY from Novartis Pharma AG of Basel, Switzerland, where he served as head of one of the mature drug discovery programs.

Dr. Urfer will be responsible for AGY's drug discovery program, which aims to and develop lead compounds to treat central nervous system diseases, including stroke, Alzheimer's disease, Parkinson's disease, depression, schizophrenia, epilepsy, brain tumors and metabolic diseases, including obesity.

"Dr. Urfer brings a decade of drug discovery experience from leading pharmaceutical to AGY, which will help us accelerate our multiple, promising programs," said Dr. Karoly Founder and Chief Executive Officer of AGY Therapeutics. "His groundbreaking work at and Novartis are relevant to us, as we make the transition from discovering targets to novel therapeutics for significant unmet medical needs in the CNS area. Dr. Urfer brings kind of experience and leadership that can help us make that happen."

Previously, Dr. Urfer served as Head of the Mature Drug Discovery Program in Department of Arthritis Biology at Novartis Pharma AG, where he led the discovery and of low-molecular weight antagonists of chemokine receptors, as well as the development of a human monoclonal antibody. At Novartis, he also was Head of the Exploratory Program with an on the identification of novel signaling modulators and disease genes.

Dr. Urfer received a Ph.D. in Biochemistry from the University of Basel, Subsequently, he worked as a postdoctoral fellow in the Department of Protein Engineering Genentech, Inc., where he delineated the molecular interactions between nerve growth and their receptors. Dr. Urfer has authored numerous publications and patents and his work at prominent scientific conventions.

AGY Therapeutics, Inc. is a privately held biopharmaceutical company focused on developing therapeutic products for the treatment of diseases of the central nervous system. With its proprietary imAGYne, imArrays and imFormatics platforms, AGY has built a unique knowledge base of the neuroprotective capacities and vulnerabilities of the nervous system.

This news release contains forward-looking statements about future research and development efforts. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that further research into these genes may not go forward as planned or that future scientific data on these genes may not provide supportive data for the diseases we are targeting.

About AGY l Research & Development l Investors & Partners l AGY News l Career Opportunities l Contact Us